BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37095742)

  • 1. A patent review of EZH2 inhibitors from 2017 and beyond.
    Wan G; Feng H; Su C; Zhu Y; Zhang L; Zhang Q; Yu L
    Expert Opin Ther Pat; 2023 Apr; 33(4):293-308. PubMed ID: 37095742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
    Dockerill M; Gregson C; O' Donovan DH
    Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EZH2 inhibitors: a patent review (2014-2016).
    Stazi G; Zwergel C; Mai A; Valente S
    Expert Opin Ther Pat; 2017 Jul; 27(7):797-813. PubMed ID: 28394193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET inhibitors: an updated patent review (2018-2021).
    Chen H; Liu Z; Zheng L; Wang R; Shi L
    Expert Opin Ther Pat; 2022 Sep; 32(9):953-968. PubMed ID: 35982031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential of enhancer of zeste homolog 2 inhibitors for the treatment of SWI/SNF mutant cancers and tumor microenvironment modulation.
    Pyziak K; Sroka-Porada A; Rzymski T; Dulak J; Łoboda A
    Drug Dev Res; 2021 Sep; 82(6):730-753. PubMed ID: 33565092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting EZH2 as cancer therapy.
    Hanaki S; Shimada M
    J Biochem; 2021 Sep; 170(1):1-4. PubMed ID: 33479735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
    Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
    Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting EZH2 for cancer therapy: From current progress to novel strategies.
    Zeng J; Zhang J; Sun Y; Wang J; Ren C; Banerjee S; Ouyang L; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114419. PubMed ID: 35569264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2-Targeted Therapies in Cancer: Hype or a Reality.
    Eich ML; Athar M; Ferguson JE; Varambally S
    Cancer Res; 2020 Dec; 80(24):5449-5458. PubMed ID: 32978169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EZH2 mutations and promoter hypermethylation in childhood acute lymphoblastic leukemia.
    Schäfer V; Ernst J; Rinke J; Winkelmann N; Beck JF; Hochhaus A; Gruhn B; Ernst T
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1641-50. PubMed ID: 27169594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
    Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
    Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
    Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PRC2-complex related dysfunction in overgrowth syndromes: A review of EZH2, EED, and SUZ12 and their syndromic phenotypes.
    Cyrus S; Burkardt D; Weaver DD; Gibson WT
    Am J Med Genet C Semin Med Genet; 2019 Dec; 181(4):519-531. PubMed ID: 31724824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The roles of EZH2 in cancer and its inhibitors.
    Liu Y; Yang Q
    Med Oncol; 2023 May; 40(6):167. PubMed ID: 37148376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of polycomb repressive complex 2 key components EZH2/SUZ12/EED as an unfavorable prognostic marker in cholangiocarcinoma.
    Wasenang W; Puapairoj A; Settasatian C; Proungvitaya S; Limpaiboon T
    Pathol Res Pract; 2019 Jul; 215(7):152451. PubMed ID: 31126817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Astemizole arrests the proliferation of cancer cells by disrupting the EZH2-EED interaction of polycomb repressive complex 2.
    Kong X; Chen L; Jiao L; Jiang X; Lian F; Lu J; Zhu K; Du D; Liu J; Ding H; Zhang N; Shen J; Zheng M; Chen K; Liu X; Jiang H; Luo C
    J Med Chem; 2014 Nov; 57(22):9512-21. PubMed ID: 25369470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-canonical transcriptional regulation of INHAT subunit SET/TAF-Iβ by EZH2.
    Hwang IJ; Park J; Seo SB
    Biochem Biophys Res Commun; 2022 Dec; 635():136-143. PubMed ID: 36274363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells.
    Li H; Cai Q; Godwin AK; Zhang R
    Mol Cancer Res; 2010 Dec; 8(12):1610-8. PubMed ID: 21115743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.